Anti-A2ML1/ CPAMD9/ OMS functional antibody
Anti-A2ML1/ CPAMD9/ OMS functional antibody for cell culture, ELISA & in-vivo assay
Go to A2ML1/A2ML1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0631-Ab-1/ GM-Tg-hg-SE0631-Ab-2 | Anti-Human A2ML1 monoclonal antibody | Human |
GM-Tg-rg-SE0631-Ab-1/ GM-Tg-rg-SE0631-Ab-2 | Anti-Rat A2ML1 monoclonal antibody | Rat |
GM-Tg-mg-SE0631-Ab-1/ GM-Tg-mg-SE0631-Ab-2 | Anti-Mouse A2ML1 monoclonal antibody | Mouse |
GM-Tg-cynog-SE0631-Ab-1/ GM-Tg-cynog-SE0631-Ab-2 | Anti-Cynomolgus/ Rhesus macaque A2ML1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0631-Ab-1/ GM-Tg-felg-SE0631-Ab-2 | Anti-Feline A2ML1 monoclonal antibody | Feline |
GM-Tg-cang-SE0631-Ab-1/ GM-Tg-cang-SE0631-Ab-2 | Anti-Canine A2ML1 monoclonal antibody | Canine |
GM-Tg-bovg-SE0631-Ab-1/ GM-Tg-bovg-SE0631-Ab-2 | Anti-Bovine A2ML1 monoclonal antibody | Bovine |
GM-Tg-equg-SE0631-Ab-1/ GM-Tg-equg-SE0631-Ab-2 | Anti-Equine A2ML1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0631-Ab-1/ GM-Tg-hg-SE0631-Ab-2; GM-Tg-rg-SE0631-Ab-1/ GM-Tg-rg-SE0631-Ab-2; GM-Tg-mg-SE0631-Ab-1/ GM-Tg-mg-SE0631-Ab-2; GM-Tg-cynog-SE0631-Ab-1/ GM-Tg-cynog-SE0631-Ab-2; GM-Tg-felg-SE0631-Ab-1/ GM-Tg-felg-SE0631-Ab-2; GM-Tg-cang-SE0631-Ab-1/ GM-Tg-cang-SE0631-Ab-2; GM-Tg-bovg-SE0631-Ab-1/ GM-Tg-bovg-SE0631-Ab-2; GM-Tg-equg-SE0631-Ab-1/ GM-Tg-equg-SE0631-Ab-2 |
Products Name | Anti-A2ML1 monoclonal antibody |
Format | mab |
Target Name | A2ML1 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-A2ML1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0631-Ag-1 | Recombinant multi-species A2ML1/ CPAMD9/ OMS protein |
Cytokine | GM-Tg-g-SE0631-Ag-1 | alpha-2-macroglobulin-like 1 (A2ML1) protein |
Target information
Target ID | GM-SE0631 |
Target Name | A2ML1 |
Gene ID | 144568,716616,486697,101101643,516769,100061421 |
Gene Symbol and Synonyms | A2ML1,CPAMD9,OMS,p170 |
Uniprot Accession | A8K2U0 |
Uniprot Entry Name | A2ML1_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Cytokine Target |
Disease | Perinatal necrotizing enterocolitis |
Gene Ensembl | ENSG00000166535 |
Target Classification | N/A |
The target: A2ML1, gene name: A2ML1, also named as CPAMD9, OMS, p170. This gene encodes a member of the alpha-macroglobulin superfamily. The encoded protein is thought to be an N-glycosylated monomeric protein that acts as an inhibitor of several proteases. It has been shown to form covalent interactions with proteases, and has been reported as the p170 antigen recognized by autoantibodies in the autoimmune disease paraneoplastic pemphigus (PNP; PMID:20805888). Mutations in these gene have also been associated with some cases of Noonan syndrome (NS; PMID:24939586) as well as some cases of otitis media (PMID:26121085). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Aug 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.